The Journal of thoracic and cardiovascular surgery
-
J. Thorac. Cardiovasc. Surg. · May 2024
Multicenter Study Clinical TrialTotal aortic arch replacement using a frozen elephant trunk device: Results of a 1-year US multicenter trial.
In this prospective US investigational device exemption trial, we assessed the safety and 1-year clinical outcomes of the Thoraflex Hybrid device (Terumo Aortic) for the frozen elephant trunk technique to repair the ascending aorta, aortic arch, and descending thoracic aorta. ⋯ One-year results with the Thoraflex Hybrid device are acceptable. Long-term data are necessary to assess the durability of these repairs.
-
J. Thorac. Cardiovasc. Surg. · May 2024
ELSO Center of Excellence Recognition Associated with Improved Failure to Rescue after Cardiac Arrest.
The influence of Extracorporeal Life Support Organization (ELSO) center of excellence (CoE) recognition on failure to rescue after cardiac surgery is unknown. We hypothesized that ELSO CoE would be associated with improved failure to rescue. ⋯ ELSO CoE status is associated with improved failure to rescue following cardiac arrest for patients undergoing cardiac surgery. These findings highlight the important role that comprehensive quality programs serve in improving perioperative outcomes in cardiac surgery.
-
J. Thorac. Cardiovasc. Surg. · May 2024
Ten-year clinical and echocardiographic follow-up of third-generation biological prostheses in the aortic position.
PERIMOUNT Magna Ease (Carpentier-Edwards; PME) prostheses have been widely implanted during the past decade for aortic valve replacement (AVR). Although promising results at midterm follow-up were reported, long-term outcome has yet to be confirmed. On this study we aimed to evaluate long-term results in terms of structural valve degeneration (SVD), major clinical outcomes, long-term hemodynamic valve performance, and left ventricular remodeling. ⋯ PME provides very good durability at long-term and could be considered one of the high performing third-generation bioprostheses for AVR.
-
J. Thorac. Cardiovasc. Surg. · May 2024
Outcomes of treatment for deep left ventricular assist device infection.
Among left ventricular assist device patients, the most commonly infected component is the drive line, which can be managed with antibiotics and local debridement. Infection of intrathoracic device components is less common but more difficult to manage. Herein we describe the incidence of deep device infection (DDI) at our center as well as management and outcomes. ⋯ DDI is a rare but challenging complication in this destination era. Heart transplantation is the preferred management strategy for eligible patients but infectious complication is common.